FDA — authorised 25 January 2013
- Application: NDA022271
- Marketing authorisation holder: TAKEDA PHARMS USA
- Local brand name: NESINA
- Indication: TABLET — ORAL
- Status: approved
🇺🇸 Nesina in United States
FDA authorised Nesina on 25 January 2013
Marketing authorisations
FDA
- Status: approved
FDA
- Application: ANDA210213
- Marketing authorisation holder: MSN LABS PVT LTD
- Local brand name: ALOGLIPTIN
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA210002
- Marketing authorisation holder: INDOCO REMEDIES
- Local brand name: ALOGLIPTIN
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA210160
- Marketing authorisation holder: TORRENT PHARMS LTD
- Local brand name: ALOGLIPTIN; METFORMIN HYDROCHLORIDE
- Indication: TABLET — ORAL
- Status: approved
Nesina in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Metabolic approved in United States
Frequently asked questions
Is Nesina approved in United States?
Yes. FDA authorised it on 25 January 2013; FDA has authorised it; FDA has authorised it.
Who is the marketing authorisation holder for Nesina in United States?
TAKEDA PHARMS USA holds the US marketing authorisation.